APMD (Apnimed) DeferredTaxAndRevenue: $30.40 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed DeferredTaxAndRevenue?

Apnimed APMD +13.64% 8 DeferredTaxAndRevenue is $30.40 Mil as of Mar. 2026. GuruFocus rates APMD with a GF Score™ of 8/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Apnimed's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $30.40 Mil.

Apnimed DeferredTaxAndRevenue Related Terms

Apnimed DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Apnimed's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed DeferredTaxAndRevenue Chart

Apnimed Annual Data
Trend Dec24 Dec25
DeferredTaxAndRevenue
25.00 97.81

Apnimed Quarterly Data
Dec24 Mar25 Dec25 Mar26
DeferredTaxAndRevenue 25.00 0.00 97.81 30.40
APMD
8GF Score
Apnimed Inc APMD
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $30.40 Mil mean?
Apnimed (APMD) has a DeferredTaxAndRevenue of $30.40 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Apnimed.
Is Apnimed's DeferredTaxAndRevenue too high?
Apnimed's current DeferredTaxAndRevenue is $30.40 Mil. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's DeferredTaxAndRevenue compare to ?
Apnimed's DeferredTaxAndRevenue of $30.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Apnimed. Apnimed's current DeferredTaxAndRevenue is $30.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current DeferredTaxAndRevenue of $30.40 Mil. The current DeferredTaxAndRevenue is $30.40 Mil. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Apnimed (APMD), the current DeferredTaxAndRevenue is $30.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price